The Bangalore-based Strides Arcolab has announced a major licensing and supply deal with Pfizer by which the world's largest drug maker would source 40 patent-free medicines, mostly cancer therapies, for sale in the US.
The financial terms of the deal or its revenue implications were not disclosed.
Expanding reach
The first drug under the arrangement would be launched this year to healthcare providers and patients in the US.
The first milestone payment would come during this quarter, a company official said.
The tie-up that includes orals and injectables, adds to Strides' growing presence in the largest drug consuming nation. Some of the drugs are approved and some are to be developed, he said.
The Bangalore-based generic drugs company and its South African partner, Aspen Pharmacare, in 2008 struck a similar supply deal with GSK, though for the emerging markets.
Mr Arun Kumar, Strides's Founder and Managing Director, said, “Partnering with Pfizer enhances our ability to reach a larger base of customers and patients in need of quality treatment options.”
Pfizer's Established Products Business Unit would take its supplies through Strides and its 50:50 subsidiaries with Aspen — Onco Laboratories Ltd and Onco Therapies Ltd.
